Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

Ana Cecilia Rodríguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Allan Hildesheim, Philip E. Castle, Diane Solomon, Robert D. Burk

Research output: Contribution to journalArticle

295 Citations (Scopus)

Abstract

Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67% (95% confidence interval [CI] = 63% to 70%) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21% (95% CI = 15% to 28%). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53%; 95% CI = 29% to 76%). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.

Original languageEnglish (US)
Pages (from-to)513-517
Number of pages5
JournalJournal of the National Cancer Institute
Volume100
Issue number7
DOIs
StatePublished - 2008

Fingerprint

Papillomavirus Infections
Infection
Confidence Intervals
Costa Rica
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Cervix Uteri
Public Health
Genotype
Polymerase Chain Reaction
Health
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. / Rodríguez, Ana Cecilia; Schiffman, Mark; Herrero, Rolando; Wacholder, Sholom; Hildesheim, Allan; Castle, Philip E.; Solomon, Diane; Burk, Robert D.

In: Journal of the National Cancer Institute, Vol. 100, No. 7, 2008, p. 513-517.

Research output: Contribution to journalArticle

Rodríguez, Ana Cecilia ; Schiffman, Mark ; Herrero, Rolando ; Wacholder, Sholom ; Hildesheim, Allan ; Castle, Philip E. ; Solomon, Diane ; Burk, Robert D. / Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. In: Journal of the National Cancer Institute. 2008 ; Vol. 100, No. 7. pp. 513-517.
@article{9c697eb6088447da9c580c673795d872,
title = "Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections",
abstract = "Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67{\%} (95{\%} confidence interval [CI] = 63{\%} to 70{\%}) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21{\%} (95{\%} CI = 15{\%} to 28{\%}). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53{\%}; 95{\%} CI = 29{\%} to 76{\%}). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.",
author = "Rodr{\'i}guez, {Ana Cecilia} and Mark Schiffman and Rolando Herrero and Sholom Wacholder and Allan Hildesheim and Castle, {Philip E.} and Diane Solomon and Burk, {Robert D.}",
year = "2008",
doi = "10.1093/jnci/djn044",
language = "English (US)",
volume = "100",
pages = "513--517",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

AU - Rodríguez, Ana Cecilia

AU - Schiffman, Mark

AU - Herrero, Rolando

AU - Wacholder, Sholom

AU - Hildesheim, Allan

AU - Castle, Philip E.

AU - Solomon, Diane

AU - Burk, Robert D.

PY - 2008

Y1 - 2008

N2 - Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67% (95% confidence interval [CI] = 63% to 70%) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21% (95% CI = 15% to 28%). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53%; 95% CI = 29% to 76%). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.

AB - Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67% (95% confidence interval [CI] = 63% to 70%) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21% (95% CI = 15% to 28%). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53%; 95% CI = 29% to 76%). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.

UR - http://www.scopus.com/inward/record.url?scp=41749106467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749106467&partnerID=8YFLogxK

U2 - 10.1093/jnci/djn044

DO - 10.1093/jnci/djn044

M3 - Article

VL - 100

SP - 513

EP - 517

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -